Atossa Therapeutics is a clinical-stage biopharmaceutical company seeking to develop medicines in areas of oncology and infectious diseases, with a focus on breast cancer, other breast conditions and COVID-19. Co.'s drug under development for breast cancer and other breast conditions is Endoxifen which is being developed primarily in two settings: one to reduce tumor cell activity in breast cancer patients in the neoadjuvant setting, meaning prior to surgery; and another to reduce dense breast tissue in women. Co.'s two COVID-19 drugs under development are: AT-H201, an inhalation therapy for COVID-19 patients; and AT-301, a nasal spray for COVID-19 patients for at-home use.
|
Free ATOS Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (4.00 out of 4) 98th percentile
(ranked higher than approx. 98% of all stocks covered)
Analysts' Target Price: ATOS Stock Forecast Based on Zacks ABR data; powered by Xignite |